Bullish Case: AMGN's Q3 beat (revenue ~$10.4B, EPS $7.14) plus the Imdelltra Phase 3 win (58% death-risk reduction in SCLC) and MariTide obesity optionality support momentum. The Helium term structure decays from 72% IV on 11/07 to ~28% by December—rich near-dated premium implies calm realized drift. Call volume runs 47% above puts, bullish risk tilt is 62%, and Helium's forecast is +1.06% with the return surface massed on modest positive holds.

Bearish Case: Shares sold off post-earnings on 'priced-for-perfection' caution at 20.1x book with $57.3B debt. Near-dated 11/06 puts trade at 58–78% IV with heavy volume (400/420/425 strikes), signaling acute event risk into this Friday. FDA warned Amgen over panitumumab promotion; Tavneos proceedings, Prolia/Xgeva biosimilar erosion (-33%), Enbrel litigation, and IRA pricing all loom. Backwardated IV flags gap risk the theta harvest may not offset.

Potential Outcomes:

1. 38% Calm drift +2–6% into Dec: term-structure decay (72→28% IV), calls leading. Falsifiable if near IV stays >45%.
2. 24% Continued post-earnings fade −5–10%: heavy put flow at 400–430 strikes. Falsifiable if $455–460 holds.
3. 18% Imdelltra/MariTide catalyst pop +6–12%. Falsifiable if IV compresses without price lift.
4. 12% Regulatory/litigation shock −10–15%: FDA docket or Opdivo suit headline.
5. 8% Macro risk-off −8–12% via SPY skew steepening (SPY surface shows persistent downside red skew).

November 04, 2026